Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bayer looking for a "mid-size M&A transaction" in oncology

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 23, 2023 12:32pm

166 Views

Post# 35511477

RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

Thanks Noteable. These figures sound more relevant every day.

Also Bayer wants to build up its immunology/oncology capacity and its precision medicine, IIRC.

That screams ONCY.

Roche and Bayer are both Swiss based.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"